Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 3, 2025

MDA-MB-436

RRID:CVCL_0623
Type: Cell Line

Proper Citation

(RRID:CVCL_0623)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0623

Proper Citation: (RRID:CVCL_0623)

Sex: Female

Defining Citation: PMID:730202, PMID:1961733, PMID:3518877, PMID:7272986, PMID:9288768, PMID:9823299, PMID:10862037, PMID:10969801, PMID:11343771, PMID:15677628, PMID:16397213, PMID:16541312, PMID:17157791, PMID:18516279, PMID:19582160, PMID:19593635, PMID:21778573, PMID:22460905, PMID:22585861, PMID:23151021, PMID:23601657, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25892236, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28287265, PMID:28889351, PMID:29273624, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: H4K8ac ChIP-seq epigenome analysis., Omics: H3K9me3 ChIP-seq epigenome analysis., Omics: H3K9ac ChIP-seq epigenome analysis., Omics: H3K79me2 ChIP-seq epigenome analysis., Omics: H3K4me3 ChIP-seq epigenome analysis., Omics: H3K4me1 ChIP-seq epigenome analysis., Omics: H3K36me3 ChIP-seq epigenome analysis., Omics: H3K27me3 ChIP-seq epigenome analysis., Omics: H3K27ac ChIP-seq epigenome analysis., Omics: H3K23ac ChIP-seq epigenome analysis., Omics: H2BK120ub ChIP-seq epigenome analysis., Omics: Glycoproteome analysis by proteomics., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Chromatin accessibility by ATAC-seq., Omics: Array-based CGH., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).,

Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Name: MDA-MB-436

Synonyms: MDA_MB_436, MDA MB 436, MDA-Mb-436, MDA-MB436, MDAMB436, MDA-436, MDA436, MB436, MD Anderson-Metastatic Breast-436

Cross References: BTO:BTO_0001568, CLO:CLO_0007639, EFO:EFO_0001214, CLDB:cl7218, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-130, BioGRID_ORCS_Cell_line:553, BioSample:SAMN03471588, BioSample:SAMN03472712, BioSample:SAMN10987901, cancercelllines:CVCL_0623, CCRID:1101HUM-PUMC000352, CCRID:3101HUMTCHu184, Cell_Model_Passport:SIDM00629, ChEMBL-Cells:CHEMBL4295382, ChEMBL-Targets:CHEMBL4296465, CLS:300278, Cosmic:809240, Cosmic:871156, Cosmic:897425, Cosmic:904382, Cosmic:934528, Cosmic:949191, Cosmic:979718, Cosmic:1010926, Cosmic:1017165, Cosmic:1027055, Cosmic:1044206, Cosmic:1044222, Cosmic:1046957, Cosmic:1071902, Cosmic:1176604, Cosmic:1287923, Cosmic:1289400, Cosmic:1309008, Cosmic:1434955, Cosmic:1609474, Cosmic:2009513, Cosmic:2164998, Cosmic:2361353, Cosmic-CLP:1240172, DepMap:ACH-000573, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240172, GEO:GSM115100, GEO:GSM149985, GEO:GSM149993, GEO:GSM150001, GEO:GSM217589, GEO:GSM344354, GEO:GSM344404, GEO:GSM350541, GEO:GSM421878, GEO:GSM783954, GEO:GSM845397, GEO:GSM847416, GEO:GSM847496, GEO:GSM844600, GEO:GSM844601, GEO:GSM887299, GEO:GSM888374, GEO:GSM1008909, GEO:GSM1053725, GEO:GSM1172982, GEO:GSM1214583, GEO:GSM1238135, GEO:GSM1374658, GEO:GSM1374659, GEO:GSM1401656, GEO:GSM1670085, GEO:GSM2258866, GEO:GSM2258867, GEO:GSM2258868, GEO:GSM2258869, GEO:GSM2258870, GEO:GSM2258871, GEO:GSM2258872, GEO:GSM2258873, GEO:GSM2258874, GEO:GSM2258875, GEO:GSM2258876, GEO:GSM2258877, GEO:GSM2258878, GEO:GSM2258879, GEO:GSM2258880, GEO:GSM2258881, GEO:GSM2258882, GEO:GSM2258883, GEO:GSM2258938, GEO:GSM2258939, GEO:GSM2258940, GEO:GSM3161722, GEO:GSM3161723, IARC_TP53:18371, IARC_TP53:26994, ICLC:HTL11005, IZSLER:BS TCL 246, LiGeA:CCLE_254, LINCS_HMS:50333, LINCS_LDP:LCL-1470, PharmacoDB:MDAMB436_905_2019, PRIDE:PXD005292, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0623, PubChem_Cell_line:CVCL_0623, SLKBase:3609, TOKU-E:2399, Wikidata:Q54904639

ID: CVCL_0623

Record Creation Time: 20250131T201334+0000

Record Last Update: 20250131T202934+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-436.

No alerts have been found for MDA-MB-436.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 813 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Anagho HA, et al. (2024) ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines. Cell reports, 43(7), 114433.

Leuzzi G, et al. (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861.

Shen Y, et al. (2024) Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. British journal of pharmacology, 181(21), 4262.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. Cancer research communications, 4(12), 3084.

Caggiano C, et al. (2024) Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. Cell reports, 43(9), 114751.

Mizunuma M, et al. (2024) Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer research communications, 4(8), 2101.

Russo S, et al. (2024) Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy. Molecular therapy. Oncology, 32(1), 200766.

Wang Z, et al. (2024) Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators. Science advances, 10(19), eadj1468.

Xu L, et al. (2024) A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell reports. Medicine, 5(5), 101511.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Schofield JH, et al. (2024) Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides. Cell reports, 43(4), 113984.

Ancona P, et al. (2024) Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors. Journal of molecular biology, 436(10), 168569.

Bharadwaj AG, et al. (2024) ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway. Molecular oncology, 18(1), 91.

Staniszewska AD, et al. (2024) Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(7), 1338.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. iScience, 27(2), 108958.

Mohammadhosseinpour S, et al. (2023) Arachidin-1, a Prenylated Stilbenoid from Peanut, Enhances the Anticancer Effects of Paclitaxel in Triple-Negative Breast Cancer Cells. Cancers, 15(2).

Honeywell ME, et al. (2023) p53 controls choice between apoptotic and non-apoptotic death following DNA damage. bioRxiv : the preprint server for biology.

Rodriguez-Berriguete G, et al. (2023) Small-Molecule Pol? Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(8), 1631.

Sennoune SR, et al. (2023) Potent Inhibition of Macropinocytosis by Niclosamide in Cancer Cells: A Novel Mechanism for the Anticancer Efficacy for the Antihelminthic. Cancers, 15(3).

Patterson-Fortin J, et al. (2023) Polymerase ? inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nature communications, 14(1), 1390.